The size of the Over the counter (OTC) drugs market in Europe has been estimated at USD 52.41 Million in 2019 and is projected to reach USD 77.30 Million by 2024 at a CAGR of 8.08% during the forecast period from 2019 to 2024.
Over the counter (OTC) drugs are the safe and effective drugs used for common ailments, and can be bought at the pharmacies and local stores, over the counter, without doctor’s prescription. Acetaminophen, aspirin and ibuprofen are the most common OTC drugs.Easy accessibility, low cost, convenience, customer-empowering qualities are the benefiting the OTC drugs market in Europe.
In Europe, public started showing pro-active approach towards the ailments and are resorting to lower-priced alternatives due to raising costs in healthcare. The cultural shift in public towards self-reliance is helping the pharma firms gain major acquisitions. These are some of the drivers that are fueling the market growth. The market growth is hindered majorly due to the issue of drug substance abuse.
This research report segmented and sub-segmented into the following categories:
Annual growth for developed nations is decreasing, while for the developing nations like Poland, the growth is stable. Ukraine and Bulgaria are the most rapidly developing markets. The governments in the EU are attempting to shift the costs to customers and are trying to save doctors’ and pharmacists’ resource costs.
Key players operating in the Europe Over The Counter (OTC) Drugs Market profiled in this report are GlaxoSmithKline, Johnson and Johnson, Novartis, Bayer, Pfizer, Sanofi and Takeda and are the top companies that contribute to North American OTC drugs market. Loss of patent protection is leading the companies switch to OTC.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Analgesics
5.1.2 Cough, Cold and Flu Products
5.1.3 Vitamins and Minerals
5.1.4 Dermatological Products
5.1.5 Gastrointestinal Products
5.1.6 Ophthalmic Products
5.1.7 Sleep Aid Products
5.1.8 Weight Loss/Diet Products
5.1.9 Others
5.2 By Formulation Type
5.2.1 Tablets
5.2.2 Liquids
5.2.3 Ointments
5.2.4 Sprays
5.3 Distribution Channels
5.3.1 Pharmacies
5.3.2 Supermarkets/Hypermarkets
5.3.3 Convenience stores
5.3.4 Others (Online Drug Stores)
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 GlaxoSmithKline
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Johnson and Johnson
8.3 Novartis
8.4 Bayer
8.5 Pfizer
8.6 Boehringer Ingelheim
8.7 Sanofi
8.8 Takeda
8.9 PGT Healthcare
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
